These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1647539)

  • 1. Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice.
    Jackson HC; Nutt DJ
    Psychopharmacology (Berl); 1991; 103(3):380-3. PubMed ID: 1647539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the involvement of opioid receptors in the action of anticonvulsants.
    Jackson HC; Nutt DJ
    Psychopharmacology (Berl); 1993; 111(4):486-90. PubMed ID: 7870991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the different types of opioid receptor involved in electroconvulsive shock-induced antinociception and catalepsy in the rat.
    Jackson HC; Nutt DJ
    J Pharm Pharmacol; 1991 Sep; 43(9):640-3. PubMed ID: 1685523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticonvulsant effects of DADLE are primarily mediated by activation of delta opioid receptors: interactions between delta and mu receptor antagonists.
    Tortella FC; Robles L; Holaday JW
    Life Sci; 1985 Aug; 37(6):497-503. PubMed ID: 2991684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
    Rogers H; Hayes AG; Birch PJ; Traynor JR; Lawrence AJ
    J Pharm Pharmacol; 1990 May; 42(5):358-9. PubMed ID: 1976787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse.
    Yajima Y; Narita M; Takahashi-Nakano Y; Misawa M; Nagase H; Mizoguchi H; Tseng LF; Suzuki T
    Brain Res; 2000 Apr; 862(1-2):120-6. PubMed ID: 10799676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditioned immunomodulation: investigations of the role of endogenous activity at mu, kappa, and delta opioid receptor subtypes.
    Perez L; Lysle DT
    J Neuroimmunol; 1997 Nov; 79(2):101-12. PubMed ID: 9394782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
    Picker MJ
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice.
    Skoubis PD; Matthes HW; Walwyn WM; Kieffer BL; Maidment NT
    Neuroscience; 2001; 106(4):757-63. PubMed ID: 11682161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia.
    Baamonde A; Lastra A; Juárez L; García V; Hidalgo A; Menéndez L
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Nov; 372(3):213-9. PubMed ID: 16283255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the delta-opioid receptor antagonist naltrindole on antinociceptive responses to selective delta-agonists in post-weanling rats.
    Crook TJ; Kitchen I; Hill RG
    Br J Pharmacol; 1992 Oct; 107(2):573-6. PubMed ID: 1330187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Profile of Naldemedine, a Peripherally Acting
    Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa-opioid receptor stimulation abolishes mu- but not delta-mediated inhibitory control of spinal Met-enkephalin release.
    Collin E; Bourgoin S; Ferhat L; Hamon M; Cesselin F
    Neurosci Lett; 1992 Jan; 134(2):238-42. PubMed ID: 1317026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
    Pacheco Dda F; Romero TR; Duarte ID
    Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of selective opioid peptide antagonists on the acquisition of pavlovian fear conditioning.
    Fanselow MS; Kim JJ; Young SL; Calcagnetti DJ; DeCola JP; Helmstetter FJ; Landeira-Fernandez J
    Peptides; 1991; 12(5):1033-7. PubMed ID: 1686930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone-induced analgesia in diabetic mice.
    Kamei J; Kawashima N; Kasuya Y
    Eur J Pharmacol; 1992 Jan; 210(3):339-41. PubMed ID: 1319338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of μ-opioid receptors reduces sensation seeking-like behavior in mice.
    Sikora M; Skupio U; Jastrzebska K; Rodriguez Parkitna J; Przewlocki R
    Behav Brain Res; 2019 Feb; 359():498-501. PubMed ID: 30500427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity.
    Katz Y; Weizman A; Pick CG; Pasternak GW; Liu L; Fonia O; Gavish M
    Brain Res; 1994 May; 646(2):235-41. PubMed ID: 8069669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.